Astrana Health Inc (ASTH)vsFresenius Medical Care Corporation (FMS)
ASTH
Astrana Health Inc
$37.98
-0.13%
HEALTHCARE · Cap: $1.89B
FMS
Fresenius Medical Care Corporation
$22.35
+0.54%
HEALTHCARE · Cap: $12.06B
Smart Verdict
WallStSmart Research — data-driven comparison
Fresenius Medical Care Corporation generates 405% more annual revenue ($19.43B vs $3.84B). FMS leads profitability with a 4.8% profit margin vs 1.1%. FMS trades at a lower P/E of 11.7x. FMS earns a higher WallStSmart Score of 58/100 (C).
ASTH
Buy56
out of 100
Grade: C
FMS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASTH.
Margin of Safety
+68.6%
Fair Value
$76.58
Current Price
$22.35
$54.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 48.5% year-over-year
Earnings expanding 110.5% YoY
Reasonable price relative to book value
Attractively priced relative to earnings
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.8% — below average capital efficiency
1.1% margin — thin
Operating margin of 3.5%
1.4% revenue growth
Grey zone — moderate risk
ROE of 7.5% — below average capital efficiency
4.8% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 48.5% demonstrates continued momentum.
Bull Case : FMS
The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 46.4x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.
Bear Case : FMS
The primary concerns for FMS are Revenue Growth, Altman Z-Score, Return on Equity. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ASTH profiles as a hypergrowth stock while FMS is a value play — different risk/reward profiles.
ASTH carries more volatility with a beta of 0.91 — expect wider price swings.
ASTH is growing revenue faster at 48.5% — sustainability is the question.
FMS generates stronger free cash flow (620M), providing more financial flexibility.
Bottom Line
FMS scores higher overall (58/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
Fresenius Medical Care Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?